基本信息

吴开杰,医学博士

副主任医师

副研究员(破格)

博士生导师

西安交通大学第一附属医院泌尿外科

西安交通大学泌尿外科研究所

联系方式

电子邮箱:kaijie_wu@163.com

联系电话:15389299128

联系地址:陕西省西安市雁塔西路277号

邮编:710061

站点计数器
研究领域

  • 去势抵抗型前列腺癌的发生机理及靶向策略
  • 膀胱癌侵袭、转移机制
  • 泌尿系统肿瘤微创手术
教育及工作经历

  • 2001.9-2008.7 西安交通大学医学院临床医学七年制专业学习,导师贺大林教授
  • 2008.9-2012.3 西安交通大学医学院免试攻读外科学博士学位,导师贺大林教授
  • 2009.10-2011.10 国家公派留学,美国University of Texas Southwestern Medical Center,导师Jer-Tsong Hsieh教授
  • 2012.3-至今 西安交通大学第一附属医院泌尿外科工作

个人简介

     亚专业为泌尿系统肿瘤,主攻方向为膀胱癌、前列腺癌等下尿路肿瘤,擅长机器人、腹腔镜及内窥镜等各种微创手术,每年主刀各类泌尿系统肿瘤手术近200台。对膀胱癌和前列腺癌的早期诊断、根治性手术、淋巴结清扫及多学科综合治疗(MDT)等积累了丰富的诊治经验。通过国家GCP培训并获得证书,作为主要参与者负责前列腺癌、膀胱癌等多项国际多中心临床研究。2018年赴加拿大蒙特利尔大学中心医院(CHUM)临床研修,2019年赴上海交通大学医学院附属仁济医院短期临床研修。

 

    担任欧洲泌尿外科学会会员、美国癌症学会会员、美国基础泌尿外科学会会员、国家自然科学基金一审专家、中国研究型医院学会泌尿外科学专委会青年委员、陕西省性学会青委会副主委、陕西省医师协会泌尿分会委员、陕西省抗癌协会外科肿瘤专业委员会委员。核心期刊《现代泌尿外科杂志》主编助理,核心期刊《中华肿瘤防治杂志》、《现代肿瘤医学》、《国际泌尿系统杂志》等杂志中青年编委。
 
    为“陕西省优秀博士学位论文”获得者,荣获“陕西省青年科技新星”。主持国家自然科学基金、国家重点研发计划等各级科研项目8项。以第一或通讯作者先后在《Clinical Cancer Research》、《Oncogene》等杂志发表SCI论文35篇。编写英文专著2部,获国家专利7项。受邀在SBUR、AUA、WCE等国际会议作报告10余次。2010年获得SBUR大会travel award奖,2014年获SBUR大会特邀报告(International Scholar Lecture)。荣获陕西省高校优秀共产党员、西安交通大学第一附属医院“十佳医师”、“五佳青年科技工作者”、“优秀教师”、“青年岗位能手”、“明日之星”、“党员标兵示范岗”、“医德考评优秀人员”等荣誉。2018年获“杨森”前列腺癌综合病例大赛全国决赛第一名。
科研项目
项目编号 项目名称 项目来源 起讫时间 承担角色 项目类别
2019YFC0121504 蓝激光手术系统多种腔道器官表浅病损汽化切割的动物器官离体实验和活体模拟手术实验 “863”高科技项目2019-1~负责人纵向项目
81572516 RASAL2调控GSK3β/β-catenin信号通路在基底样膀胱癌肺转移中的作用及机制研究 国家自然科学基金项目2016-1~负责人纵向项目
81202014 DAB2IP 调节雄激素-AR 信号通路在去势抵抗型前列腺癌进展中的作用研究 国家自然科学基金项目2013-1~负责人纵向项目
共有3条记录 共有1页面 每页面显示 条记录 页索引: 1 链接到第 页面
发表论文

代表论文(第一或通讯作者)、参编著作:

 

1.       Hui K, Wu SQ, Yue YY, Gu YN, Guan B, Wang XY, Hsieh JT, Chang LS, He DL, Wu KJ. RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer. Cell Signal, 2018 Aug; 48: 38-44. (SCI收录,IF=3.487,通讯作者)

 

2.       Wu KJ, Pei XQ, Tian G, Jiang YM, Wu DP, Fan JH, He DL. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian J Androl, 2018 Mar-Apr;20(2):173-177.(SCI收录,IF=3.259)

 

3.       Wang B*, Lo UG*, Wu KJ*, Kapur P, Liu XY, Huang J, Chen W, Hernandez E, Santoyo J, Ma SH, Pong RC, He DL, Chen YQ, Hsieh JT. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. Int J Cancer, 2017, Nov 15;141(10):2121-2130.(SCI收录,IF=7.360,共同第一作者)

 

4.       Pei XQ, He DL, Tian G, Lv W, Jiang YM, Wu DP, Fan JH, Wu KJ. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol, 2017, 49(4): 629-635.(SCI收录,IF=1.692,通讯作者)

 

5.       Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, Fan JH, Wang XY, Yue YY, Wu SQ, Hsieh JT, He DL, Wu KJ. RASAL2, a RAS GTPase activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis, 2017, 8: e2600.(SCI收录,IF=5.638,通讯作者)

 

6.       Wang B, Huang J, Zhou JC, Hui K, Xu S, Fan JH, Li L, Wang XY, Hsieh JT, He DL, Wu KJ. DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell Signal, 2016, 28: 1623–1630.(SCI收录,IF=3.487,通讯作者)

 

7.       Huang J, Wang B, Hui K, Zeng J, Fan JH, Wang XY, Hsieh JT, He DL, Wu KJ. miR-92b targets DAB2IP to promote EMT for bladder cancer migration and invasion. Oncol Rep, 2016, 36: 1693-1701.(SCI收录,IF= 2.976,通讯作者)

 

8.       Zhou JC*, Luo JH*, Wu KJ*, Kapur P, Yun EJ, Pong RC, Du YF, Wang B, Authement C, Hernandez E, Yang JC, Cha TL, Wu HC, Margulis V, Lotan Y, Brugarolas J, He DL, Hsieh JT. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene, 2016; 35(35): 4663-74.(SCI收录,IF=6.854,共同第一作者)

 

9.       Zhou JC, Zhu GD, Huang J, Li L, Du YF, Gao Y, Wu DP, Wang XY, Hsieh JT, He DL, Wu KJ. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett, 2016 Jan 28, 370(2):313-323.(SCI收录,IF=6.491,通讯作者)

 

10.   Wu KJ, Wang B, Chen YL, Zhou JC, Huang J, Hui K, Zeng J, Zhu JN, Zhang K, Li L, Guo P, Wang XY, Hsieh JT, He DL, Fan JH. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Cell Signal, 2015 Sep 26;27(12):2515-2523. (SCI收录,IF=3.487)

 

11.   Zhou J, Ning Z, Wang B, Yun EJ, Zhang T, Pong RC, Fazli L, Gleave M, Zeng J, Fan J, Wang X, Li L, Hsieh JT, He D, Wu K. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis. Cell Death Dis, 2015, Oct 29;6:e1955.(SCI收录,IF=5.638,通讯作者)

 

12.   Wei JH*, Haddad A*, Wu KJ*, Zhao HW, Kapur P, Zhang ZL, Zhao LY, Chen ZH, Zhou YY, Zhou JC, Wang B, Yu YH, Cai MY, Xie D, Liao B, Li CX, Li PX, Wang ZR, Zhou FJ, Shi L, Liu QZ, Gao ZL, He DL, Chen W, Hsieh JT, Li QZ, Margulis V, Luo JH. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun, 2015 Oct 30;6:8699.(SCI收录,IF=12.353,共同第一作者)

 

13.   Zhou JC, Deng Z, Chen YL, Gao Y, Wu DP, Zhu GD, Li L, Song WB, Wang XY, Wu KJ#, He DL#. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma. Urol Oncol, 2015, 33: 113.e9–113.e17.(SCI收录,IF=3.397,共同通讯作者)

 

14.   Zhou JC*, Wu KJ*, Gao DX, Zhu GD, Wu DP, Wang XY, Chen YL, Du YF, Song WB, Ma ZK, Authement C, Saha D, Hsieh JT, He DL. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radio-resistance of renal cell carcinoma. Int J Radiat Oncol Biol Phys, 2014; 90(4):942-951.(SCI收录,IF= 5.554,共同第一作者)

 

15.   Ma YM*, Wu KJ*, Dang Q, Shi Q, Gao Y, Guo P, Xu S, Wang XY, Gong YG, He DL. Testosterone regulates keratin 33B expression in rat penis growth through androgen receptor signaling. Asian J Androl, 2014; 16(5):817-823.(SCI收录,IF=3.259,共同第一作者)

 

16.   Wu KJ, Ning ZY, Zhou JC, Wang B, Fan JH, Zhu JC, Wang XY, Hsieh JT, He DL. 2'-hydroxyflavanone inhibits prostate tumor growth through inactivating AKT/STAT3 signaling and inducing cell apoptosis. Oncol Rep, 2014; 32(1):131-138.(SCI收录,IF= 2.976)

 

17.   Ma YM*, Wu KJ*, Ning L, Zeng J, Kou B, Xie HJ, Ma ZK, Wang XY, Gong YG, He DL. Relationship between androgen receptor CAG repeat polymorphism, sex hormone and penile length in Han adult men from China: a cross-sectional study. Asian J Androl, 2014; 16(3):478-81.(SCI收录,IF=3.259,共同第一作者)

 

18.   Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene, 2014 Apr 10;33(15):1954-63. (SCI收录,IF=6.854).

 

19.   Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, Guo P, Li L, Wang X, He D. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal, 2013 Dec;25(12):2625-33. (SCI收录,IF=3.487)

 

20.   Wu K, Zeng J, Zhou J, Fan J, Chen Y, Wang Z, Zhang T, Wang X, He D. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Urol Oncol, 2013 Nov;31(8):1751-60. (SCI收录,IF=3.397)

 

21.   Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT. The mechanism of DAB2IP in chemo-resistance of prostate cancer cells. Clin Cancer Res, 2013 Sep 1;19(17):4740-9. (SCI收录,IF=10.199).

 

22.   Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, Chen Y, Zhang T, Wang X, Hsieh JT, He D.  PI3K/Akt to GSK3β/β-catenin Signaling Cascade Coordinates Cell Colonization for Bladder Cancer Bone Metastasis through Regulating ZEB1 Transcription. Cell Signal, 2012 Dec;24(12):2273-82. (SCI收录,IF=3.487)

 

23.   Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF, Kapur P, He D, Hsieh JT. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol, 2012 Sep;26(9):1496-507. (SCI收录,IF=3.678,封面文章)

 

24.   Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D. Silibinin reverses epithelial to mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep, 2010 Jun;23(6):1545-52.(SCI收录,IF= 2.976)

 

25.   Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L, Fan JH, Wang XY, He DL. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing Vimentin and MMP-2 Expression. Acta Pharmacol Sin, 2009 Aug;30(8):1162-8.(SCI收录,IF=3.562)

 

26.   Yun EJ, Wu KJ, Tsai YS, Xie DX, Hsieh JT. The functional role of DAB2IP, a homeostatic factor, in prostate cancer. Prostate Cancer: Biochemistry, Molecular Biology and Genetics (Editor: Donald J. Tindall). Chapter, 2013, Springer Science Publishers.

 

27.   He DL, Li L, Wu KJ. Update of the most recent advances in the treatment of metastatic castration-resistant prostate cancer. Prostate Cancer Cells: Detection, Growth and Treatment (Editor: Zongbing You). Chapter, 2012, Nov. Nova Science Publishers.